

Herpes Simplex Virus Treatment Market by Type (Herpes simplex virus-1 infection and Herpes simplex virus-2 infection), Drug type (Acyclovir, Valacyclovir and Famciclovir), Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027

<https://marketpublishers.com/r/H339AFABAC84EN.html>

Date: July 2023

Pages: 321

Price: US\$ 4,500.00 (Single User License)

ID: H339AFABAC84EN

Abstracts

Herpes simplex virus is one of the highly usual sexually transmitted infections (STIs). It is a viral infection which affects humans. There are two forms of herpes simplex virus such as herpes simplex virus-1 (HSV-1) and herpes simplex virus-2 (HSV-2). HSV-1 is commonly related to oral herpes or cold sores. It may also leads to genital herpes through oral sex. HSV-2 is typically related to genital herpes and also causes oral herpes through oral sex. Rise and innovations in the pharmaceutical industry for the production of herpes simplex virus drugs generates an opportunity for the herpes simplex virus treatment market. Surge in awareness regarding the risks and problems of herpes simplex virus infection have resulted in an increased demand for effective treatments. This has resulted in high screening and diagnosis of HSV infection, further propelling the growth of the market. On the contrary, the social stigma related with sexually transmitted diseases, along with the surging product recalls are factors restraining market. The Herpes Simplex Virus Treatment Market is likely to grow at a rate of 2.0% CAGR by 2027.

Herpes Simplex Virus Treatment Market by Type

Herpes simplex virus-1 infection

Herpes simplex virus-2 infection

Herpes Simplex Virus Treatment Market by Drug type

Acyclovir
Valacyclovir
Famciclovir

Herpes Simplex Virus Treatment Market by Distribution channel

Hospital pharmacies
Drug store and retail pharmacies
Online providers

Herpes Simplex Virus Treatment Market by Geography

North America
Europe
Asia Pacific
Rest of the World

The type segmentation is segmented as Herpes simplex virus-1 infection and Herpes simplex virus-2 infection. Herpes simplex virus-1 infection segment holds the vital share in the market. The rising incidence of Herpes simplex virus-1 infection is a key factor for the vital share of the segment. Furthermore, the rising pressure of Herpes simplex virus-1 encephalitis (HSE), a rare neurological disorder caused by the virus, is projected to augment the growth of the segment.

The Drug type segmentation is classified into Acyclovir, Valacyclovir and Famciclovir. The Valacyclovir segment has the maximum share in the market. This is owing to the availability, cost-effectiveness and effectiveness provided by valacyclovir in stopping the herpes virus from reproducing in the body, thus helping to reduce the symptoms of a herpes outbreak. Further, the valacyclovir is highly used for cold sores ascribed to its extensive absorption rate as acyclovir is broken down by the liver easily when consumed orally.

Based on distribution channel segmentation, the market is divided into Hospital Pharmacies, Drug Store and Retail Pharmacies and Online Providers. Hospital Pharmacies segment held the dominant share in the market. Since, these pharmacies are the major centers for the diagnosis and treatment of patients suffering from herpes

infections in both developed and developing nations.

North America region is leading the market share on the basis of geography. The leading share of the segment is accredited to the increased consumption of branded herpes drugs, rising healthcare expenditure, rising introduction of generics, beneficial reimbursement policies and rising disease prevalence in the region are the key factors.

Furthermore, the increasing global health expenditure and government support to fulfill the surging demand for effective therapeutics are promoting companies to engage in creating new and innovative medicines. For example, in June 2021, Innovative Molecules GmbH, a Munich-based drug development company, declared positive results of its new drug candidate, IM-250, a second-generation helicase-primase inhibitor of HSV-1 and HSV-2 in different animal models of HSV. The company received USD 23.8 million in series A equity funding led by Life Sciences Partners and projects commencing Phase 1 clinical trials of IM-250 in late 2022 or early 2023.

The major leading companies of the herpes simplex virus treatment market are Viatrix Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Limited, Fresenius SE and Co. KGaA, Teva Pharmaceutical Industries Ltd., Abbott Laboratories, GlaxoSmithKline plc, Pfizer Inc., Novartis AG, Emcure Pharmaceuticals Limited

Therefore, the herpes simplex virus is the disease which does not have a complete treatment but the medications are available which are playing a significant part in suppressing the frequency and quantity of genital herpes among people. Moreover, the awareness has increased among people regarding the herpes simplex virus which has increased the market demand.

An exclusive analysis of all key geographical regions is included in the report which determines the potential opportunities in these regions.

Detailed information about the attributes which are generating growth in the herpes simplex virus treatment market in the forecast period.

An exact estimation of the herpes simplex virus treatment market share and its contribution to the parent market is provided in the report.

Further profiles of leading competitors and their dynamic strategies are also covered in the study.

Contents

1. EXECUTIVE SUMMARY

2. INDUSTRY OUTLOOK

2.1. Industry Overview

2.2. Industry Trends

3. MARKET SNAPSHOT

3.1. Market Definition

3.2. Market Outlook

3.2.1. Porter Five Forces

3.3. Related Markets

4. MARKET CHARACTERISTICS

4.1. Market Overview

4.2. Market Segmentation

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. DRO - Impact Analysis

5. TYPE: MARKET SIZE & ANALYSIS

5.1. Overview

5.2. Herpes simplex virus-1 infection

5.3. Herpes simplex virus-2 infection

6. DRUG TYPE: MARKET SIZE & ANALYSIS

6.1. Overview

6.2. Acyclovir

6.3. Valacyclovir

6.4. Famciclovir

7. DISTRIBUTION CHANNEL: MARKET SIZE & ANALYSIS

- 7.1. Overview
- 7.2. Hospital pharmacies
- 7.3. Drug store and retail pharmacies
- 7.4. Online providers

8. GEOGRAPHY: MARKET SIZE & ANALYSIS

- 8.1. Overview
- 8.2. North America
- 8.3. Europe
- 8.4. Asia Pacific
- 8.5. Rest of the World

9. COMPETITIVE LANDSCAPE

- 9.1. Competitor Comparison Analysis
- 9.2. Market Developments
 - 9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
 - 9.2.2. Product Launches and execution

10. VENDOR PROFILES

- 10.1. Viatris Inc.
 - 10.1.1. Overview
 - 10.1.2. Financial Overview
 - 10.1.3. Product Offerings
 - 10.1.4. Developments
 - 10.1.5. Business Strategy
- 10.2. Amneal Pharmaceuticals LLC
 - 10.2.1. Overview
 - 10.2.2. Financial Overview
 - 10.2.3. Product Offerings
 - 10.2.4. Developments
 - 10.2.5. Business Strategy
- 10.3. Glenmark Pharmaceuticals Limited
 - 10.3.1. Overview
 - 10.3.2. Financial Overview

- 10.3.3. Product Offerings
- 10.3.4. Developments
- 10.3.5. Business Strategy
- 10.4. Fresenius SE and Co. KGaA
 - 10.4.1. Overview
 - 10.4.2. Financial Overview
 - 10.4.3. Product Offerings
 - 10.4.4. Developments
 - 10.4.5. Business Strategy
- 10.5. Teva Pharmaceutical Industries Ltd.
 - 10.5.1. Overview
 - 10.5.2. Financial Overview
 - 10.5.3. Product Offerings
 - 10.5.4. Developments
 - 10.5.5. Business Strategy
- 10.6. Abbott Laboratories
 - 10.6.1. Overview
 - 10.6.2. Financial Overview
 - 10.6.3. Product Offerings
 - 10.6.4. Developments
 - 10.6.5. Business Strategy
- 10.7. GlaxoSmithKline plc
 - 10.7.1. Overview
 - 10.7.2. Financial Overview
 - 10.7.3. Product Offerings
 - 10.7.4. Developments
 - 10.7.5. Business Strategy
- 10.8. Pfizer Inc.
 - 10.8.1. Overview
 - 10.8.2. Financial Overview
 - 10.8.3. Product Offerings
 - 10.8.4. Developments
 - 10.8.5. Business Strategy
- 10.9. Novartis AG
 - 10.9.1. Overview
 - 10.9.2. Financial Overview
 - 10.9.3. Product Offerings
 - 10.9.4. Developments
 - 10.9.5. Business Strategy

10.10. Emcure Pharmaceuticals Limited

- 10.10.1. Overview
- 10.10.2. Financial Overview
- 10.10.3. Product Offerings
- 10.10.4. Developments
- 10.10.5. Business Strategy

11. ANALYST OPINION

12. ANNEXURE

- 12.1. Report Scope
- 12.2. Market Definitions
- 12.3. Research Methodology
 - 12.3.1. Data Collation and In-house Estimation
 - 12.3.2. Market Triangulation
 - 12.3.3. Forecasting
- 12.4. Report Assumptions
- 12.5. Declarations
- 12.6. Stakeholders
- 12.7. Abbreviations

List Of Tables

LIST OF TABLES

- TABLE 1. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
- TABLE 2. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HERPES SIMPLEX VIRUS-1 INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 3. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HERPES SIMPLEX VIRUS-2 INFECTION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 4. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 5. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR ACYCLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 6. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR VALACYCLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 7. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR FAMCICLOVIR, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 8. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
- TABLE 9. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 10. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR DRUG STORE AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 11. GLOBAL HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
- TABLE 12. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
- TABLE 13. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)
- TABLE 14. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)
- TABLE 15. NORTH AMERICA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)
- TABLE 16. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 17. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 18. U.S HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 19. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 20. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 21. CANADA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 22. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 23. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 24. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 25. EUROPE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 26. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 27. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 28. GERMANY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 29. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 30. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 31. U.K HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 32. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 33. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 34. FRANCE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 35. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 36. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY

DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 37. ITALY HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 38. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 39. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 40. SPAIN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 41. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 42. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 43. ROE HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 44. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 47. ASIA PACIFC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 48. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 49. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 50. CHINA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 51. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 52. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 53. INDIA HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 54. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 55. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 56. JAPAN HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 57. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 59. REST OF APAC HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 60. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DRUG TYPE, 2021-2027 (USD BILLION)

TABLE 62. REST OF WORLD HERPES SIMPLEX VIRUS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 63. VIATRIS INC.: FINANCIALS

TABLE 64. VIATRIS INC.: PRODUCTS & SERVICES

TABLE 65. VIATRIS INC.: RECENT DEVELOPMENTS

TABLE 66. AMNEAL PHARMACEUTICALS LLC: FINANCIALS

TABLE 67. AMNEAL PHARMACEUTICALS LLC: PRODUCTS & SERVICES

TABLE 68. AMNEAL PHARMACEUTICALS LLC: RECENT DEVELOPMENTS

TABLE 69. GLENMARK PHARMACEUTICALS LIMITED: FINANCIALS

TABLE 70. GLENMARK PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES

TABLE 71. GLENMARK PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS

TABLE 72. FRESENIUS SE AND CO. KGAA: FINANCIALS

TABLE 73. FRESENIUS SE AND CO. KGAA: PRODUCTS & SERVICES

TABLE 74. FRESENIUS SE AND CO. KGAA: RECENT DEVELOPMENTS

TABLE 75. TEVA PHARMACEUTICAL INDUSTRIES LTD.: FINANCIALS

TABLE 76. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS & SERVICES

TABLE 77. TEVA PHARMACEUTICAL INDUSTRIES LTD.: RECENT DEVELOPMENTS

TABLE 78. ABBOTT LABORATORIES: FINANCIALS

TABLE 79. ABBOTT LABORATORIES: PRODUCTS & SERVICES

TABLE 80. ABBOTT LABORATORIES: RECENT DEVELOPMENTS

TABLE 81. GLAXOSMITHKLINE PLC: FINANCIALS

TABLE 82. GLAXOSMITHKLINE PLC: PRODUCTS & SERVICES

TABLE 83. GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS

TABLE 84. PFIZER INC.: FINANCIALS

TABLE 85. PFIZER INC.: PRODUCTS & SERVICES

TABLE 86. PFIZER INC.: RECENT DEVELOPMENTS

TABLE 87. NOVARTIS AG: FINANCIALS

TABLE 88. NOVARTIS AG: PRODUCTS & SERVICES

TABLE 89. NOVARTIS AG: RECENT DEVELOPMENTS

TABLE 90. EMCURE PHARMACEUTICALS LIMITED: FINANCIALS

TABLE 91. EMCURE PHARMACEUTICALS LIMITED: PRODUCTS & SERVICES

TABLE 92. EMCURE PHARMACEUTICALS LIMITED: RECENT DEVELOPMENTS

I would like to order

Product name: Herpes Simplex Virus Treatment Market by Type (Herpes simplex virus-1 infection and Herpes simplex virus-2 infection), Drug type (Acyclovir, Valacyclovir and Famciclovir), Distribution channel (Hospital Pharmacies, Drug Store and Retail Pharmacies and Online Providers) and Geography (North America, Europe, APAC and RoW)-Forecast up to 2027

Product link: <https://marketpublishers.com/r/H339AFABAC84EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H339AFABAC84EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970